Drug Trial Radar · NCT05432960
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2023
Primary completion
Aug 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Exacte Labs LLC; Ministry of Health, Russian Federation; Scientific Center EFiS LLC; Data Management 365
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.
Conditions
- Adult-Onset Still's Disease
- AOSD
Interventions
RPH-104Biological
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
PlaceboDrug
Normal Saline (0.9% Sodium Chloride solution)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time (number of days) to exacerbation during 24 weeks after randomization while taking RPH-104 vs placebo in patients with AOSDTime frame: from randomization (visit 16, week 29) to exacerbation, up to week 53
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Institute of Rheumatology. V.A. Nasonova
Moscow, Russia
Clinic of Nephrology, Internal and Occupational Diseases. EAT. Tareeva, University Clinical Hospital No. 3
Moscow, Russia
State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology
Saint Petersburg, Russia
FGBU "National Medical Research Center named after V.A. Almazov", Ministry of Health of the Russian Federation, Department of Rheumatology
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.